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SUMMARY
Dynamic nuclear SUMO modifications play essential
roles in orchestrating cellular responses to proteo-
toxic stress, DNA damage, and DNA virus infection.
Here,wedescribe anon-canonical host SUMOylation
response to the nuclear-replicating RNA pathogen,
influenza virus, and identify viral RNA polymerase ac-
tivity as a major contributor to SUMO proteome re-
modeling. Using quantitative proteomics to compare
stress-induced SUMOylation responses, we reveal
that influenza virus infection triggers unique re-tar-
geting of SUMO to 63 host proteins involved in tran-
scription, mRNA processing, RNA quality control,
and DNA damage repair. This is paralleled by wide-
spread host deSUMOylation. Depletion screening
identified ten virus-induced SUMO targets as poten-
tial antiviral factors, including C18orf25 and the
SMC5/6 and PAF1 complexes. Mechanistic studies
further uncovered a role for SUMOylation of the
PAF1 complex component, parafibromin (CDC73),
in potentiating antiviral gene expression. Our global
characterization of influenza virus-triggered SUMO
redistribution provides a proteomic resource to un-
derstand host nuclear SUMOylation responses to
infection.
INTRODUCTION
Reversible posttranslational modification of proteins provides
cells with a rapid and dynamic mechanism to modulate prote-
ome functionality in response to many stimuli, including path-
ogen invasion. Ubiquitin and ubiquitin-like modifiers (Ubls)
have emerged as central players in mediating the host innate im-
mune response to infection, and their diversity, coordination by
specialized enzymatic cascades, and range of linkage topol-
ogies all contribute to an incredibly rich regulatory potential.
Among Ubls, the small ubiquitin-like modifiers (SUMOs) are pre-
dominantly located in the cell nucleus, and they are reversibly
attached to lysine residues in target proteins by only a small
set of known enzymes (Hay, 2013). Nevertheless, SUMOs can
conjugate to thousands of proteins (Hendriks et al., 2014; Tamm-
salu et al., 2014) and regulate distinct cellular processes, such as
transcription, chromatin remodeling, DNA repair, and cell-cycle
progression.
The SUMO conjugation machinery is highly responsive to
stress stimuli, with global changes to SUMOylation occurring
rapidly after cells have been exposed to heat shock (Golebiowski
et al., 2009; Saitoh and Hinchey, 2000), proteasome inhibition
(Lamoliatte et al., 2014; Tatham et al., 2011), or DNA damage
(Hendriks et al., 2015; Yin et al., 2012). Thus, stress-triggered
SUMOylation modulates nuclear functions as part of a resolution
strategy to protect cell integrity. Recent studies also have impli-
cated SUMOylation as playing a critical role in activating host
intracellular pathogen defenses, particularly against DNA viruses
that enter the nucleus (Boutell et al., 2011; Cuchet-Lourenc¸o
et al., 2011), but also against HIV-1 (Li et al., 2012) and bacteria
(Fritah et al., 2014; Ribet et al., 2010). As such, many DNA vi-
ruses, as well as some bacteria, encode proteins that actively
suppress host SUMOylation or reduce the global amount of
SUMO conjugates in infected cells (Everett et al., 2013; Ribet
et al., 2010). Notably, with clear parallels to the SUMOylation
response triggered by environmental stresses, a nuclear-repli-
cating HSV-1 mutant lacking the ability to degrade SUMO-modi-
fied proteins induces increased SUMO conjugate formation
during infection and is restricted by an active SUMO system
(Boutell et al., 2011). This suggests that cells sense DNA virus
infection stress in the nucleus and (in the absence of a path-
ogen-encoded antagonist) respond by enhancing SUMOylation
of certain targets to suppress replication.
Influenza viruses are atypical RNA viruses that replicate in
host-cell nuclei and encode multiple proteins that become
SUMOylated during infection in order to regulate their trafficking
or function (Han et al., 2014; Santos et al., 2013; Wu et al., 2011;
Xu et al., 2011). The inextricable linking of influenza viruses to
nuclei is further exemplified by the coupling of viral RNA tran-
scription to that of the host, the viral re-purposing of host-cell
RNA splicing machinery, and the tethering of viral RNA genomes
to cellular chromatin (Fodor, 2013). We speculated that the repli-
cation strategy of these nuclear RNA pathogens may induce a
form of nuclear stress akin to that of an invading DNA virus,
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thereby resulting in an analogous host SUMOylation response
to resolve infection. Here we show that global remodeling of
the host SUMO system is induced by nuclear-replicating influ-
enza virus infections, but not other cytoplasmic-replicating
RNA virus infections, and that influenza viral polymerase activity
in the nucleus is a key contributor to this SUMO response.
Furthermore, we utilize a system-wide quantitative mass spec-
trometry approach to identify the SUMO-modified proteome of
human lung epithelial cells, and we quantify changes in host
SUMO modification during influenza A virus (IAV) infection.
Combining our proteomic results with a targeted gene-depletion
screen and mechanistic studies, we uncover a host SUMOyla-
tion response to IAV infection that is distinct from that trig-
gered by other cellular stresses, and we reveal several potential
pro- and antiviral host factors whose function is regulated by
SUMO. These data form a comprehensive proteomic and func-
tional resource to understand the nuclear SUMO response to
an RNA virus infection.
RESULTS
Nuclear-Replicating Influenza Viruses Induce Specific
Remodeling of Host SUMOConjugation and Localization
Human cells express three main SUMO paralogues as follows:
SUMO2 and SUMO3, which only differ by 3 amino acids in their
mature state (hereafter referred to as SUMO2/3); and SUMO1,
which shares 50% sequence identity with SUMO2/3. Consis-
tent with the results of others (Pal et al., 2011), western blot anal-
ysis of total human lung epithelial cell (A549) lysates revealed
that IAV infection triggers an increase in the abundance of pro-
teins modified by both SUMO1 and SUMO2/3, whereas the
amounts of free, unconjugated SUMO1 and SUMO2/3 are
depleted (Figure 1A). This SUMOylation response is not due to
an increase in SUMO mRNA transcripts during infection (Fig-
ure S1A), indicating that new SUMO conjugates arise from the
pre-existing SUMO pool. Furthermore, this response is not
unique to IAV, as influenza B virus (which also replicates in the
nucleus) triggered similar SUMO conjugate induction during
infection (Figure 1B). Nevertheless, infection with a panel of
cytoplasmic-replicating RNA viruses (including members of the
Bunyaviridae [ve sense, segmented RNA genome], Rhabdovir-
idae [ve sense, single-stranded RNA genome], and Togaviridae
[+ve sense, single-stranded RNA genome]) revealed that these
viruses do not trigger gross SUMO conjugate induction (Fig-
ure 1C). These data suggest a specific induction of SUMO con-
jugates in response to nuclear-replicating influenza viruses.
To further characterize SUMO remodeling during IAV infec-
tion, we studied the intracellular distribution of SUMO1 and
SUMO2/3. SUMOs normally form discrete intra-nuclear foci
(10–20 per cell), a fraction of which co-localizes with promyelo-
cytic leukemia (PML) nuclear bodies (PML NBs) (Everett et al.,
2013). In addition, a sub-population of SUMO1 localizes to the
nuclear rim. We found that, concomitant with SUMO conjugate
induction, IAV infection triggers dispersal of both SUMO1 and
SUMO2/3 nuclear puncta (Figures 1D and S1B), a phenotype
similar to that observed in response to DNA damage and heat
shock stresses (Hendriks et al., 2015; Nefkens et al., 2003).
Notably, components of PML NBs (such as hDaxx and SP100)
also disperse during IAV infection, but PML itself only redistrib-
utes into smaller, yetmore numerous, foci (Figure 1E). A strikingly
similar specific redistribution of PML NB components has been
observed previously in response to heat shock (Nefkens et al.,
2003). However, western blotting did not reveal gross changes
in PML SUMOylation following IAV infection (Figure S1C), sug-
gesting that this SUMO remodeling is specific to certain cellular
substrates. These data indicate that IAV-induced SUMO remod-
eling causes a redistribution of SUMO from sites including PML
NBs to new targets that are distributed diffusely throughout the
nucleus.
Influenza Virus RNA Polymerase Activity Contributes to
Host SUMO Remodeling
IAV-triggered SUMOylation was not abrogated in cells function-
ally deficient in the cytoplasmic innate immunemediatorsMAVS,
IRF3, and STAT1 (Figure S2A). Furthermore, there was no
change in the kinetics of IAV-induced SUMOylation when small
interfering RNAs (siRNAs) were used to deplete infected cells
of NS1, the major IAV interferon antagonist (Figure S2B). In
addition, an IAV infection-like SUMOylation response was not
observed following type I/II interferon stimulation or following
stimulation of canonical innate immune responses by a defec-
tive-interfering particle-rich stock of Sendai virus (Figure S2C).
These data are consistent with previous observations discon-
necting IAV-induced SUMOylation from interferon responses
(Pal et al., 2011). We therefore hypothesized that a form of
viral stress distinct from that triggering classical innate immune
pathways may be responsible for IAV-induced SUMOylation.
However, an IAV-like broad SUMO response could not be trig-
gered using chemical stimuli promoting ER stress, DNA damage,
or apoptosis, three canonical cellular stresses we suspected
might occur during IAV infection, but that were not active at times
when IAV-stimulated SUMOylation was apparent (Figures S2D
and S2E).
We used small-molecule inhibitors and UV-inactivation
methods to map IAV-triggered SUMOylation to a process re-
quiring viral genome replication and protein synthesis, but not
genome nuclear export or later stages of the virus replication
cycle, such as virion budding (Figure 2A). Given the tight associ-
ation of active influenza virus replication complexes with nuclear
processes (a distinguishing feature from cytoplasmic-replicating
RNA viruses), we speculated that the stress of nuclear IAV
polymerase activity may contribute to host SUMO remodeling.
To test this hypothesis, we used a transfection-based mini-
replicon reporter system, whereby viral ribonucleoprotein com-
plexes (vRNPs) consisting of viral NP, PB1, PB2, and PA are
assembled together in the nucleus following plasmid expression
along with a negative-sense viral-like RNA genomic segment en-
codingmCherry. As the viral-like RNA cannot be transcribed into
mRNA by cellular polymerases, mCherry protein is only pro-
duced in cells expressing all five viral components. Furthermore,
the mCherry construct is unspliced such that this assay recapit-
ulates IAV RNA transcription and replication, but not splicing.
Using SUMO foci dispersion as a single-cell readout of host
SUMO proteome remodeling, we found that cells expressing
actively replicating IAV RNP complexes had significantly fewer
SUMO1 and SUMO2/3 foci than cells expressing all the viral
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protein components of the RNP in the absence of viral-like RNA
or mock-transfected cells (Figures 2B and 2C). In addition,
expression of each individual vRNP component, or negative-
sense viral RNA together with NP, failed to stimulate SUMO re-
modeling (Figures 2D and 2E). To assess directly the contribution
of viral polymerase activity (rather than basic processes such as
RNP formation) on SUMO redistribution, we also tested inactive
RNPs in this assay, either by omitting an essential polymerase
Figure 1. SUMOConjugation Patterns and Intracellular Distribution following Infectionwith a Panel of Nuclear- andCytoplasmic-Replicating
RNA Viruses
(A) Western blot of lysates from A549s infected with IAV (5 PFU/cell) as indicated. SUMO1, SUMO2/3, NS1, and actin were detected.
(B and C) Western blot of Vero cells infected with IAV or influenza B virus (IBV) for 16 hr at 33C (B) or infected with IAV, LACV, VSV, or SFV for 12 hr at 37C (all5
PFU/cell) (C). SUMO2/3, actin, and individual viral proteins were detected.
(D and E) Immunofluorescent analysis and quantification of MRC5s infected with IAV at 0.1 PFU/cell as indicated. SUMO1 and SUMO2/3 (D) or hDaxx, SP100,
PML (E), and IAV NP were visualized after staining. Scale bars represent 5 mm. Statistical significance (***p < 0.0001) in (D) was determined using the Student’s t
test. See also Figure S1.
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component or by substituting in a mutant polymerase. In both
cases, polymerase activity was completely abrogated, as deter-
mined by standard mini-replicon assays, and concomitantly
there was a significant relief in RNP-triggered SUMO redistribu-
tion (Figure 2F). Overall, these data suggest that IAV RNA poly-
merase activity in the nucleus (transcription processes or repli-
cation enhancing vRNA/cRNA levels, but probably not splicing)
is a stimulus for triggering remodeling of the host SUMO system
during infection, and they are consistent with the hypothesis that
virus-induced SUMOylation is specific to nuclear-replicating vi-
ruses, rather than RNA viruses in general. We propose that IAV
polymerase activity in the nucleus triggers a previously unappre-
ciated form of nuclear stress that is regulated by SUMOylation.
SILAC-Based Quantitative Proteomics of IAV-Induced
SUMO Remodeling
To survey the dynamics of cellular and viral protein SUMOylation
during IAV infection, we adopted a quantitative proteomic strat-
egy that has been used previously to identify changes in SUMO
modification in response to proteotoxic stresses (Golebiowski
et al., 2009; Tatham et al., 2011). We generated A549 cell lines
stably expressing either SUMO1 or SUMO2 fused to an N-termi-
nal tandem affinity purification (TAP) tag. An additional A549 cell
line stably expressing the TAP tag only (TAP only) was generated
as a negative control (Figures S3A and S3B). Both heterologous-
ly expressed TAP-SUMO1 and TAP-SUMO2 conjugated to
endogenous cellular proteins under normal growth conditions
in the respective cell lines, and conjugation of these tagged
SUMO forms was robustly enhanced following IAV infection (Fig-
ure S3C), indicating that the tag did not interfere with SUMO
conjugation and that these constructs faithfully recapitulate
endogenous SUMOylation changes in response to infection.
We conducted two independent stable isotope labeling by
amino acids in cell culture (SILAC) experiments to determine
the impact of IAV infection for 10 hr on the SUMO1 and
SUMO2 sub-proteomes of A549 cells (Figure 3A). This time point
was chosen to ensure all infected cells had undergone a full
single cycle of virus replication and to capture primary dynamic
SUMOylation changes. Notably, <2% of cellular proteins varied
in total abundance more than 2-fold either between the TAP-
only and TAP-SUMO cell lines or after IAV infection (Figures
S3D and S3E). In contrast, analysis of the purified samples
showed that 32% (SUMO1) and 47% (SUMO2) of quantified
proteins were >2-fold more abundant in the purified TAP-SUMO
material compared with the purified TAP-only material, and
36% (SUMO1) and 25% (SUMO2) of quantified proteins var-
ied >2-fold in abundance in the purified TAP-SUMO material
following IAV infection (Figures S3F and S3G). Together, this
suggests that a large proportion of identified and quantified
proteins in the purified, but not crude, samples show specific
changes in abundance relating to SUMO modification status,
as well as a dependence upon infection for SUMO conjugation
state.
Using a false discovery threshold of 1%, we identified and
quantified 587 putative SUMO1 substrates and 815 putative
SUMO2 substrates in A549 cells (Figure 3B; Tables S1 and
S2). Bioinformatic comparison of the combined 895 putative
SUMO substrates with those identified in independent studies
using different cell types revealed that 89% of our assigned
SUMO substrates have been described as SUMO targets previ-
ously (Figure S3H; Table S3). We identified 506 putative sub-
strates as common to both SUMO1 and SUMO2 (Figure S3I),
and, consistent with the roles of SUMO, gene ontology analysis
using the Enrichr platform (Chen et al., 2013) revealed enrich-
ment of these substrates for cellular compartments including
the nucleolus, nucleoplasm, chromatin, and PML NBs as well
as molecular function enrichment for chromatin binding, tran-
scription coactivator/corepressor activity, histone binding, and
transcription factor binding (Table S3). Furthermore, >76% of
these common SUMO substrates recently have been confirmed
as bona fide SUMO substrates by high-resolution mass spec-
trometry-based SUMO modification site-mapping techniques,
which identify SUMO-modified lysine residues (Table S4). Such
a high degree of overlap with other studies, combined with the
gene ontology analysis, supports the validity of our approach
in identifying SUMO substrates in human lung A549 cells.
Triple SILAC maps (tsMAPs) of the putative host SUMO sub-
strates illustrated that, surprisingly, the bulk of substrates ex-
hibited reduced SUMO modification (357 for SUMO1 and 245
for SUMO2) or unchanged SUMOylation following IAV infection
(Figure 3B; Tables S1 and S2). Strikingly, only 76 SUMO1 sub-
strates (13%) and 117 SUMO2 substrates (14%) increased sub-
stantially in SUMO modification status (up to 35-fold) during
IAV infection (Figure 3B; Tables S1 and S2). Thus, although the
Figure 2. IAV Polymerase Activity Contributes to SUMO Remodeling
(A) Western blot of lysates from IAV-infected A549 cells treated with different inhibitors. Cells were infected with IAV or UV-inactivated IAV (UV) at 5 PFU/cell,
followed by incubation with 50 mg/ml cycloheximide (CHX), 11 nM leptomycin B (LMB), or 10 mM zanamivir (Zan) for 12 hr. SUMO1, SUMO2/3, NS1, NP, and actin
were detected. (Bottom) Immunofluorescence shows NP staining at 12 hr post-infection in A549s ± LMB. DAPI was used to stain DNA.
(B and C) Immunofluorescent analyses of MRC5s transiently expressing PB1, PB2, PA, NP, and a negative-sense viral-like mini-replicon mCherry reporter
construct (+vRNA), or PB1, PB2, PA, NP, and mCherry (no viral-like reporter; vRNA).
(D) Immunofluorescent analysis of MRC5s individually expressing PB1, PB2, PA, or NP.
(E) Immunofluorescent analysis ofMRC5s transiently transfectedwith pDZ-NP, which expresses both NP protein from a pol-II promoter and NP vRNA from a pol-I
promoter.
(F) (Top) Luciferase-basedmini-replicon assays in 293Ts to assess polymerase activity. (Left) (WSN, H1N1) Cells transiently expressing PB1 (or not), PB2, PA, NP,
and a negative-sense viral-like mini-replicon Firefly luciferase reporter construct. (Right) (KAN-1, H5N1) Cells transiently expressing PB1 (or an E445A/E446A
inactivemutant), AvianPr-PB2-E627K, PA, NP, and a negative-sense viral-likemini-replicon Firefly luciferase reporter construct. Bars representmean values from
triplicates (±SD). (Bottom) Quantification of SUMO1 nuclear foci for the conditions indicated above as determined by the mCherry-based mini-replicon reporter
assay in MRC5s. For (B)–(F), cells were transfected for 36 hr prior to processing or fixation and immunostaining. Representative images are shown. Scale bars
represent 5 mm. Statistical significance in panels (B), (C), (E), and (F) was determined using the Student’s t test (***p < 0.0001; ns, non-significant). See also
Figure S2.
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original western blotting experiments suggested an overall in-
crease in SUMOylation upon infection, it is clear that IAV-
induced SUMOylation of substantial numbers of substrates
occurs concomitantly with the deSUMOylation of a different
set of proteins. Notably, protein deSUMOylation occurred to a
much lower extent (maximum8-fold decrease) than SUMOyla-
tion, suggesting widespread dynamic exchange of SUMOduring
infection from the bulk of pre-existing substrates to a restricted
set of new cellular targets.
Comparison of the quantitative changes to SUMO1 and
SUMO2 conjugation in response to IAV infection demonstrated
a high degree of correlation (Pearson’s coefficient of 0.89) (Fig-
ure 3C), indicating no gross differences between SUMO1 and
SUMO2 paralogues, although some paralogue-specific SUMO
Figure 3. Quantitative SUMO Proteomics of IAV-Infected Cells
(A) SILAC-based SUMO1 and SUMO2 proteomic workflow. The specified A549s were grown for five to six cell doublings in light (L; isotopically normal, K0R0),
medium (M; K4R6), or heavy (H; K8R10) SILAC medium prior to treatment and processing as indicated.
(B) The tsMAPs of SUMO1 (left) and SUMO2 (right) substrates after data filtering, indicating log2-fold changes in protein modification following IAV infection (y
axis). The numbers of substrates identified in each category are indicated and certain examples are highlighted.
(C) Correlation of log2-fold changes in SUMO1 and SUMO2 substrate modification following IAV infection. The 63 substrates that increase (and 158 substrates
that decrease) in both SUMO1 and SUMO2 modification following IAV infection are highlighted, and certain example proteins are labeled.
(D) The 63 host substrates that increase in SUMOylation with IAV infection organized by manually curated functional category. See also Figure S3 and Tables S1,
S2, S3, S4, and S7.
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modification changes were observed (Table S3). Thus, the com-
bined SUMO1 and SUMO2 data represent a common and
stringent consensus of SUMO substrate changes following IAV
infection. Using such criteria, we define 63 host proteins as
increasing in SUMOmodification with IAV infection and 158 pro-
teins as decreasing in SUMO modification (Figures 3C and 3D;
Table S3).
Validation of IAV-Induced Host SUMOylation
Remodeling
We took both a biochemical and a bioinformatic approach to
validate the SILAC ratios obtained for IAV-induced SUMOylation
changes. Given that only a small proportion of any given sub-
strate population is usually SUMO modified, detection of conju-
gated forms of proteins is notoriously difficult without prior
enrichment. We therefore used immunoblotting for endogenous
cellular proteins to analyze SUMO1 and SUMO2 immunoprecip-
itation samples from IAV-infected A549s or TAP purification
samples from independent IAV infections of the TAP-only,
TAP-SUMO1, and TAP-SUMO2 cell lines. As shown in Figures
4A and S4, we could validate the IAV-enhanced conjugation of
SUMO1 and SUMO2 to endogenous cellular proteins, such as
CDC73, UBTF, and ATRX. Interestingly, we also confirmed
IAV-enhanced conjugation of SUMO2 in the TAP-SUMO1 sam-
ples, suggestive of a possible increase in SUMO1-capped
SUMO2 chains or the increased conjugation of both SUMO1
and SUMO2 to the same target proteins. We also confirmed
our mass spectrometry data that RanGAP1 and PML are basally
SUMOylated but largely do not change in modification status
following IAV infection, whereas TRIM28 is highly deSUMOy-
lated during infection. Importantly, independent western blot
analysis of total A549 cell lysates following infection revealed
that the abundance of the major unconjugated forms of all these
target proteins does not increase in response to IAV infection, an
observation consistent with the mass spectrometry quantifica-
tion of each protein in crude lysates and indicative of a specific
effect of infection on SUMO modification status (Figures 4A
and S4; Tables S1 and S2).
To further validate the IAV-triggered host SUMOylation
changes for additional targets without suitable antibodies avail-
able, we developed a slice-by-slice bioinformatic analysis based
on scrutinizing the change in electrophoretic mobility of target
proteins in TAP-SUMO2-purified mass spectrometry samples
in response to IAV infection. First, using mass spectrometry
data obtained from individual gel slices, we compared themigra-
tion pattern of selected putative targets in total crude lysates
with their migration pattern in TAP-SUMO2-purified samples,
defining each target as SUMO2 modified if it migrated slower
in the purified sample than expected based on its predicted mo-
lecular weight. In addition, for each target and gel slice, we
analyzed the change in peptide ratio upon IAV infection in the
TAP-SUMO2-purified samples in order to determine the magni-
tude of SUMOylation change at a given mobility.
As shown in Figure 4B, such an analysis of SUMO2 revealed
that during IAV infection SUMO2 shifted from a faster migrating
species (its unconjugated form) to several slower migrating spe-
cies distributed throughout multiple gel slices, indicating that
increased SUMO2 conjugation during IAV infection is partly a
Figure 4. Western Blot and Bioinformatic Validation of IAV-Induced
SUMO Targets
(A) TAP-purified (left) or crude lysate (right) samples from specified A549s
either mock or IAV infected were subjected to western blot analysis for the
indicated substrates.
(B) Predicted molecular weight (preMW) of substrates (unmodified) was
compared to their observed electrophoretic mobility (obsEM) across all 13
slices (crude and TAP-SUMO2 purified, IAV/Mock). Yellow background in-
dicates slice where unmodified protein would be expected based on its
preMW. Bar length indicates change in protein ratio between IAV- and mock-
infected (H/M) purified TAP-SUMO2 samples. Intensity of color indicates
protein abundance (intensity) in each slice; red was nominally given to
increased H/M ratios while blue was nominally given to decreased H/M ratios.
Asterisks indicate obsEM of specified proteins in crude lysate. See also Fig-
ures S4 and S5.
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consequence of depleting unmodified SUMO2. Strikingly, similar
analyses revealed that host protein examples, such as CDC73,
UBTF, NDNL2, C18orf25, and ZRANB2, all migrated slower
than expected in the TAP-SUMO2-purified samples (indicative
of their SUMO2 modification), and their abundance in these
slower migrating forms was highly enhanced upon IAV infection
(indicative of increased SUMOylation). In contrast, host proteins
such as TRIM28 and DPF2 also migrated slower than expected
in TAP-SUMO-purified samples, although their abundance in
these fractions decreased with infection, suggesting a decrease
in their SUMOylation that correlated with the mass spectrometry
and western blot analyses (Figure 4B). These validation exam-
ples further strengthened the confidence in our mass spectrom-
etry dataset as a whole.
IAV Proteins as SUMO Targets
Several IAV proteins have been described as targets for SUMO
modification (Pal et al., 2011; Santos et al., 2013; Wu et al.,
2011; Xu et al., 2011). Analysis of our TAP-SUMO-enriched
mass spectrometry data using a stringent 1% false discovery
threshold and our slice-by-slice bioinformatic strategy revealed
that only NS1, M1, and NEP satisfied our filtering criteria for
SUMO1- and SUMO2-modified targets during infection (Figures
S3F, S3G, and S5A). NS1 and M1 have been studied extensively
as SUMO targets, but NEP has not previously been identified as
a bona fide SUMO substrate during IAV infection. These mass
spectrometry data therefore support the rationale for future
studies investigating functional consequences of viral protein
SUMOylation.
IAV-Induced Host SUMOylation Responses Are Distinct
from Those Triggered by Canonical Stress Stimuli
A multitude of stresses has been demonstrated to modulate
cellular SUMO modification dynamics, including heat shock,
ionizing radiation, proteotoxicity, and bacterial infection. Strik-
ingly, heat shock causes a global increase in total SUMO
conjugates that, by western blot, appears similar to that
observed with IAV infection (Figure 5A). To compare the cellular
SUMOylation response to IAV with the response to heat shock
treatment, we also used SILAC proteomics to determine how
the SUMO2-modified proteome changes in TAP-SUMO2 A549
cells following incubation at 43C for 30 min (Figure 5A; Table
Figure 5. The IAV-Induced Host SUMOylation Response Is Quantitatively Distinct from that Induced by Other Stresses
(A) Quantitative SUMO2 proteomics of the heat shock response in A549s. The indicated A549s were grown for five to six cell doublings in light (L; isotopically
normal, K0R0), medium (M; K4R6), or heavy (H; K8R10) SILAC medium prior to treatment (for 30 min) as indicated. Subsequent TAP purification and analyses
were performed as for Figure 3. Graph shows tsMAP of SUMO2 substrates after data filtering, indicating log2-fold changes in protein modification following heat
shock (y axis).
(B–F) Correlations show log2-fold changes in SUMO2 modification in response to heat shock between HeLa and A549 cells (B); between IAV infection and heat
shock in A549 cells (C); between IAV infection in A549 cells and proteasome inhibition (MG132) in HeLa cells (D); between IAV infection in A549 cells and Shigella
flexneri infection in HeLa cells (E); and between IAV infection in A549 cells and ionizing radiation (IR; 15 Gy) in HeLa cells (F). See also Figure S5 and Table S5.
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S5). Heat-shock-triggered SUMO2 conjugation changes in
A549s strongly correlated with those previously determined in
HeLa cells using similar methodologies (Golebiowski et al.,
2009), thereby confirming the validity of our data and indicating
that this cellular stress induces a cell-type-independent SUMO
response (Pearson’s coefficient of 0.89, Figure 5B). Neverthe-
less, the IAV-triggered SUMOylation response in A549s did not
quantitatively correlate with the heat shock SUMOylation
response (Pearson’s coefficient of 0.43) (Figure 5C).
Furthermore, given that our analysis of A549 and HeLa heat
shock data indicated a common SUMO response in both A549
and HeLa cells, we took advantage of several HeLa SUMO pro-
teomic datasets generated under various stress conditions
(Fritah et al., 2014; Tatham et al., 2011; Yin et al., 2012) and
compared them with our IAV-induced SUMO response in
A549s. Notably, we also did not find a correlation between the
IAV-induced SUMO response and the SUMO responses to pro-
teasome inhibition (MG132 treatment), infection with Shigella
flexneri, or ionizing radiation (Figures 5D–5F). On a qualitative
level, bioinformatic analysis revealed distinct pathways that
were enriched in enhanced SUMOylation following individual
stresses (Table S7). For example, IAV-induced SUMOylation tar-
gets were enriched in members of the human PAF1 complex
(PAF1C) and several categories relating to RNA polymerase II
function, while Shigella flexneri-induced targets were enriched
in centromer chromatin complex members. Heat shock stress
caused SUMO to redistribute to a wider range of targets, with
themost enriched categories including the spliceosome, the pol-
ycomb repressive complex, and the DNA synthesome complex
(Table S7). These comparative observations suggest that IAV
infection triggers a host SUMOylation response that is phenotyp-
ically distinct from responses to canonical cellular stresses,
highlighting a potentially unique stress to the cell induced by viral
RNA polymerase activity in the nucleus.
shRNA Screening Identifies IAV-Triggered SUMO
Targets as Pro- and Antiviral Host Factors
Consistent between our SUMO1 and SUMO2 proteomic studies,
IAV infection triggered a >4-fold increase in SUMOylation of 42
host proteins. To identify functional roles for these core SUMO
targets during IAV infection, we depleted A549 cells of the corre-
sponding 42 genes one by one using small hairpin RNA (shRNA)-
expressing lentiviruses (three per gene), and we determined the
subsequent replication of IAV by measuring infectious virus
yields at 24 and 48 hr post-infection (Figure 6A). As controls,
we also assessed the impact on IAV replication of depleting
IRF3, a host antiviral defense transcription factor, and ATP6V0C,
a vacuolar ATPase component required for efficient IAV entry
(Ko¨nig et al., 2010). We classified a host gene as important for
IAV replication if at least two of three shRNAs increased or
decreased infectious IAV yields by at least 5-fold at a minimum
of one time point compared to the non-targeting shRNA.
Using these criteria, we identified ten putative host antiviral
factors among the IAV-induced SUMO targets and two required
factors (Figure 6B; Table S6). For several of these factors, inde-
pendent experiments confirmed that the shRNAs efficiently
Figure 6. SUMO Targets Impacting IAV Replication
(A) Schematic representation of the lentivirus-based shRNA screen assessing 42 host SUMO targets for their impact on IAV replication.
(B) Heatmap summary of factors identified as required or restrictive to IAV replication in A549 cells. Genes are shown whose depletion led to a 5-fold or more
difference in infectious IAV titer as compared with control for at least two of three shRNA sequences. Each individual shRNA is labeled a, b, or c and control
shRNAs are highlighted in gray.
(C–E) Validation of PAF1 (C), C18orf25 (D), and AFF4 (E) as impacting IAV replication. The two shRNA sequences for each gene from (B) that showed consistent
impact on IAV replication were independently validated in the same assay for their effect on IAV replication (top) and specific gene knockdown and effect on cell
viability (bottom). Bars represent mean values from triplicates (±SD). See also Table S6.
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depleted the target host mRNA, had minimal effect on cell
viability, and reproducibly impacted IAV replication (Figures
6C–6E; Table S6). Notably, our shRNA screen identified three
members of the human SMC5/6 complex (SMC5, SMC6, and
the SUMO E3 ligase NSMCE2) as potential IAV antiviral factors,
along with three members of PAF1C (PAF1, CTR9, and CDC73)
and twoPAF1C-associated proteins (SSRP1 and CFDP1). These
data indicate that the IAV-triggered SUMOylation response tar-
gets both pro- and antiviral host factors, and they suggest a
thus far unknown role for the humanSMC5/6DNAdamage repair
complex in IAV restriction.
SUMOylation of CDC73 Promotes Antiviral Gene
Expression
In our proteomic screen, all components of PAF1C increased
highly in SUMOylation during IAV infection (Figure S5B), and
PAF1C was the most highly enriched functional group among
all the substrates with infection-enhanced SUMOylation (Table
S7). An antiviral role for the PAF1 component of PAF1C during
IAV infection has been previously attributed to its potentiation
of interferon-stimulated gene (ISG) expression (Marazzi et al.,
2012). However, the contribution of SUMO modification to this
process is unknown. To explore mechanistically how IAV-trig-
gered SUMOylation may impact the function of PAF1C, we
focused follow-up studies on CDC73 (also known as parafibro-
min or HRPT2), a core component of PAF1C with SUMO modifi-
cation sites recently mapped by mass spectrometry (Hendriks
et al., 2014; Lamoliatte et al., 2014; Tammsalu et al., 2014),
and which our shRNA screening data revealed as a potential
host antiviral factor.
In agreement with the antiviral role of PAF1 in mediating RNA
polymerase II transcription elongation of ISGs (Marazzi et al.,
2012), we found that siRNA-mediated depletion of endogenous
CDC73 resulted in defective induction of ISG15 mRNA following
IFNa treatment (Figure 7A). In addition, overexpression of
CDC73 alone was able to stimulate expression from a promoter
containing an interferon-stimulated response element (ISRE) in a
dose-dependent manner (Figure 7B). The effect of CDC73 over-
expression was not limited to ISRE-containing promoters, as a
similar enhancing effect was observed for an NF-kB promoter,
although minimally for the IFNb promoter reporter, indicating a
degree of specificity in CDC73’s capacity to regulate inducible
gene expression (Figure 7C). Promoter stimulation in these as-
says was specific to CDC73 overexpression, as co-transfection
of siRNAs targeting CDC73 mRNA ablated protein production
downstream of the ISRE promoter (Figure 7D). Furthermore,
consistent with a model for CDC73 acting in RNA polymerase
II-mediated transcription elongation, we found that the effect
of CDC73 on ISRE promoter-driven expression was insensitive
to depletion of the STAT1 transcription factor, which is otherwise
essential for IFNa-stimulated activation of the ISRE (Figure 7E).
These data suggest that CDC73 may act as an antiviral factor
by potentiating inducible antiviral gene expression at a level sub-
sequent to transcription factor activation.
To evaluate the role of CDC73 SUMO modification in tran-
scription of inducible genes, such as ISGs, we assessed the
ability of CDC73 to stimulate the ISRE reporter in the context
of co-expressed human SENP2, a deSUMOylating enzyme pre-
viously implicated in regulating host antiviral responses (Ran
et al., 2011). We found that SENP2 was able to antagonize
CDC73-mediated activation of the ISRE reporter, suggesting
that SUMOylation of CDC73 is important for this function (Fig-
ure 7F). In addition, we screened the ISRE-stimulating capabil-
ities of a panel of three CDC73 mutants with lysine-to-arginine
substitutions at sites positively identified by mass spectrometry
to be SUMO modified using high-confidence remnant immu-
noaffinity profiling methods (Lamoliatte et al., 2014; Tammsalu
et al., 2014). Notably, the single K136R substitution abrogated
CDC73-mediated ISRE-dependent expression, while arginine
substitutions at lysines 301 and 385 did not abrogate this res-
ponse (Figure 7G).
Recent studies have validated CDC73-K136 as a bona fide
SUMO modification site in vitro using purified recombinant
proteins (Lamoliatte et al., 2014). We found that K136 is a
major site for CDC73 SUMOylation in transfected cells, with
the K136R substitution alone leading to highly reduced levels
of SUMO-modified CDC73 (Figure 7H). K136 is located within
an NLS of CDC73, and the arginine substitution at this site
also leads to a subtle shift in the nuclear-cytoplasmic distribution
of CDC73 (Figure S6), which may be indicative of SUMO
modification contributing to the nuclear retention of CDC73.
We note that CDC73 SUMOylation can be enhanced by other
cellular stresses, including heat shock (Figure S5C), and interest-
ingly the CDC73-K136R SUMOylation mutant has been previ-
ously shown to be defective in localizing to PMLNBs in response
to proteotoxic stress (Lamoliatte et al., 2014). Based on
these data, we propose a general function for stress-triggered
CDC73 SUMOylation in regulating stress-inducible genes that
are required for resolution of cell integrity. With regard to virus
infection, IAV-induced SUMOylation of CDC73 appears to
potentiate its function in transcription elongation of genes pro-
moting antiviral immunity.
DISCUSSION
The role of SUMO modifications in resolving cellular stress con-
ditions and responding to DNA virus infections in the nucleus is
well established (Everett et al., 2013; Hay, 2013). Here we report
the induction of a host SUMOylation response to nuclear-repli-
cating RNA viruses, exemplified by the important human and
animal pathogens, influenza A and B viruses. For nuclear-repli-
cating DNA viruses, the incoming naked DNA molecule has
been suggested to trigger SUMOylation in a manner analogous
to damaged cellular DNA (Cuchet-Lourenc¸o et al., 2011). In our
study, we found that active viral RNA polymerase function is a
major trigger for SUMO remodeling, suggesting that this foreign
activity in the nucleus induces a previously unappreciated form
of stress to which the host raises a SUMO response. It is
currently unknownwhich aspect of viral RNA polymerase activity
might induce SUMO remodeling, although our unspliced repli-
con data suggest that viral hijack of the host RNA-splicing ma-
chinery is not a major stimulus. A key question to resolve will
be whether IAV-induced SUMOylation is a specific response
to infection or a generalized response to nuclear stress. For
example, with parallels to cytoplasmic RIG-I, a nuclear pathogen
sensor might be activated by newly synthesized IAV RNA to
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Figure 7. SUMO Modification Promotes the
Function of CDC73 in Mediating an ISG
Response
(A) Impact of CDC73 knockdown on ISG expres-
sion. A549s were transfected for 48 hr with four
independent siRNAs targeting CDC73 (or scram-
bled) before stimulation with 100 IU/ml IFNa for
8 hr. The mRNA levels of CDC73, ISG15, and
GAPDH were quantified. (Left) IFNa-mediated in-
duction of ISG15 mRNA relative to mock is shown.
(B) Induction of an ISRE-containing promoter by
overexpressed CDC73. 293Ts were co-trans-
fected with expression plasmids encoding FLAG-
tagged mCherry or CDC73 (12.5–200 ng) together
with pGL3-Mx1P-FFluc and pRL-SV40. After 36 hr,
FF luciferase activity was determined and normal-
ized toRenilla. Parallel samples were harvested for
western blot, probing for the indicated proteins.
(C) Impact of CDC73 overexpression on NF-kB
(left) and IFNb (right) promoters. 293Ts were co-
transfected with FLAG-tagged mCherry or CDC73
(200 ng) together with pNF-kB-FFLuc (or p125-
FFLuc) and pRL-SV40. Control for NF-kB pro-
moter activation was 10 ng/ml TNF-a for 12 hr
(+ve); control for IFNb promoter activation was co-
transfection of 20 ng RIG-I2CARD (+ve). After
36 hr, relative activity was determined as in (B).
(D) The siRNAs targeting CDC73 abrogate the ef-
fect of CDC73 overexpression on inducible gene
expression. 293Ts were transfected/processed as
in (B) except four independent siRNAs targeting
CDC73 (or scrambled) also were transfected.
(E) CDC73-mediated induction of an ISRE-con-
taining promoter is independent of STAT1 func-
tion. 293Ts were co-transfected with expression
plasmids encoding FLAG-tagged mCherry or
CDC73 (100 ng) together with plasmids encoding
GST or PIV5-V (100 ng) and pGL3-Mx1P-FFluc
and pRL-SV40. Control cells were stimulated with
100 IU/ml IFNa. Then, 36 hr post-transfection,
relative activity was determined as in (B). Data
represent fold induction in promoter activation
relative to mCherry-expressing cells.
(F) CDC73-mediated induction of an ISRE-con-
taining promoter is dependent on SUMOylation.
Experiment was as in (E) except plasmids encod-
ing GST or SENP2 (100 ng) were co-transfected.
(G)TheK136SUMOylationsite inCDC73 isessential
for stimulating inducible gene expression. Experi-
ment was as in (B) but included a panel of FLAG-
tagged CDC73 lysine mutants (wild-type [WT];
K136R; K301R; K385R; or a triple mutant, 3KR).
(H) K136 is a major SUMOylation site in CDC73.
293Ts were co-transfected with expression plas-
midsencodingFLAG-taggedCDC73-WTorCDC73-
K136R, together with 6His-tagged SUMO2-GG or
SUMO2-AA. Following denaturing Ni2+ pull-down,
purified proteins were detected by western blot with
anti-6Hisoranti-FLAG.For all graphs, bars represent
mean values from triplicates (±SD) and are derived
from three independent experiments. Statistical
significance was determined using the Student’s
t test (*p < 0.01, **p < 0.001, and ***p < 0.0001; ns,
non-significant). See also Figure S6.
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stimulate SUMOylation. Alternatively, the cell could simply be
reacting to infection-driven changes in the levels of specific
host factors, such as ribonucleosides depleted by IAV polymer-
ase activity or uncapped host RNAs generated by viral cap
snatching. Given the close physical association of IAV RNPs
with host chromosomes (Chase et al., 2011), it is possible that
infection induces a non-canonical DNA damage-like SUMO
response. In this regard, tethering of viral RNAs to chromatin
may mimic aberrant RNA:DNA hybrids reminiscent of R loops,
a situation in which SUMOylation plays an important resolving
role (Richard et al., 2013).
Several studies have shown that SUMO is important for
different aspects of IAV replication, predominantly by directly
modifying viral proteins (Han et al., 2014; Santos et al., 2013;
Wu et al., 2011; Xu et al., 2011). Experimentally assessing
the global contribution of SUMOylation to virus infection is
confounded by the integral nature of key SUMO components
to cellular activities. For example, the sole SUMO E2 enzyme
(Ubc9), several SUMO proteases, and SUMO2 itself are all
essential for embryonic development (Kang et al., 2010; Nacerd-
dine et al., 2005; Wang et al., 2014), and SUMO1-deficient mice
are only viable due to functional compensation by SUMO2/3 (Ev-
dokimov et al., 2008). Furthermore, depletion of Ubc9 is difficult
to establish in tissue culture and results in extensive cell-cycle
defects and loss of cell viability (Boutell et al., 2011). Thus, in
this study, we rationally undertook to identify and characterize
only the IAV-responsive SUMO proteome. Using quantitative
proteomics, we revealed an IAV-driven reprogramming of host
SUMOylation that is both quantitatively and qualitatively distinct
from previously characterized SUMO stress responses. This
dataset provided the framework for us to perform targeted
functional analysis of a specific IAV-induced SUMO substrate,
CDC73, without the need to deplete the entire SUMO system.
Our data provide a resource to continue such studies with other
IAV-induced SUMO substrates.
Proteins that change in SUMOylation status during IAV in-
fection are involved in a diverse range of nuclear biological
processes and regulatory pathways (Figure 3D; Table S7).
Consistent with viral RNA polymerase activity triggering SUMO
remodeling, we found that IAV infection retargets SUMO to
many proteins involved in chromatin remodeling or RNA polymer-
ase II transcription, including chromodomain DNA-binding heli-
cases (CHD1, CHD2, and CHD8), the FACT complex (SSRP1
and SUPT16H), transcription initiation factors (TAF1 and TAF3),
the PAF1 complex (PAF1, CTR9, RTF1, LEO1, and CDC73), and
other transcription elongation factors (AFF4, EAF1, HTATSF1,
IWS1, MLLT3, and SUPT5H). Several infection-induced SUMO
targets also are involved in mRNA maturation events, such as 30
end pre-mRNA processing (CPSF1, CPSF2, FIP1L1, RBBP6,
and WDR33), splicing (CLASRP, SFPQ, and ZRANB2), and nu-
clear RNA quality control (ZC3H18, ZCCHC7, and PAPD5).
In addition, despite being unable to detect an IAV-induced
canonical DNA damage response, we identified an infection-
responsive increase in the SUMOylation of a remarkable number
of host proteins that function in DNA damage repair, such as
BLM, EME1, the SUMO E3 ligase PIAS4, the ubiquitin E3 ligases
RAD18 and RNF111, and almost all members of the human
SMC5/6 complex. Functional screening by ourselves and others
has shown that a number of these IAV-induced SUMO targets
are required for efficient IAV propagation (Karlas et al., 2010;
Landeras-Bueno et al., 2011; Naito et al., 2007) or act as IAV re-
striction factors (Marazzi et al., 2012). Notably, we identified
three members of the SMC5/6 complex (SMC5, SMC6, and
the SUMO E3 ligase NSMCE2) as potential antiviral factors, indi-
cating that DNA damage repair proteins may play additional
roles in resolving IAV infection. These data suggest that nuclear
RNA virus replication stress can be channelled into SUMO-
dependent effector pathways shared with cellular DNA repair
processes.
We identified all components of the PAF1 complex as IAV-
triggered SUMO targets. PAF1 itself, as well as CTR9, recently
has been implicated as a positive regulator of antiviral and pro-
inflammatory gene expression (Marazzi et al., 2012; Parnas
et al., 2015; Youn et al., 2007), and genetic deletion of the
CDC73 component of PAF1C in mouse embryonic fibroblasts
led to reduced expression levels of several known ISGs,
including Ddx58, Trim21, Mov10, Isg20, Stat2, and Bst2 (Wang
et al., 2008). Here our mechanistic studies revealed a role for
SUMOylation of CDC73 in promoting ISG expression. These
data thereby directly link one consequence of the IAV-triggered
SUMOylation response to antiviral defense. Given that CDC73
SUMOylation has been described to be important for its traf-
ficking in response to proteotoxicity (Lamoliatte et al., 2014)
and CDC73 SUMOylation also is enhanced by heat shock,
we hypothesize a general function for stress-triggered CDC73
SUMOylation in regulating stress-inducible gene expression.
Our SUMO proteomic datasets and functional characteriza-
tion now provide a platform to address the role of selected pro-
tein groups and their SUMO modification in the IAV replication
cycle. This is complemented by existing proteomic studies
that recently have mapped SUMO modification sites in most
of the targets we identified here (Table S4). IAV infection causes
a global reprogramming of the host SUMOylation landscape,
the specific temporal dynamics of which have yet to be fully
explored. The resources presented here will add a layer of
post-translational understanding to previous transcriptomic,
proteomic, and genome-wide depletion studies that have sought
to gain insights into the extensive interplay between influenza
viruses and their hosts (Josset et al., 2014; Karlas et al., 2010;
Ko¨nig et al., 2010; Shapira et al., 2009).
EXPERIMENTAL PROCEDURES
Cells and Viruses
HEK 293T, A549, Vero, and MDCK cells were maintained in DMEM supple-
mented with 10% (v/v) fetal calf serum (FCS), 100 units/ml penicillin, and
100 mg/ml streptomycin (Life Technologies). MRC5 cells were maintained in
Eagle’s minimal essential medium (EMEM, Sigma) supplemented with 10%
(v/v) FCS, 100 units/ml penicillin, 100 mg/ml streptomycin, 2 mM L-Glutamine,
and 1% (v/v) Non-Essential Amino Acids (Life Technologies). Generation of
A549 cells stably expressing TAP or TAP-SUMO proteins is described in the
Supplemental Experimental Procedures. IAV (A/WSN/33) was propagated
and titrated by standard plaque assay inMDCKs, while influenza B virus (B/Ya-
magata/88) and Sendai virus were propagated in 10-day-old embryonated
chicken eggs. La Crosse encephalitis virus (LACV), vesicular stomatitis virus
(VSV), and Semliki Forest virus (SFV) were propagated and titrated by plaque
assay in Vero cells. UV inactivation of IAV was performed on ice with UV
irradiation (254 nm) for 1 min at a distance of 7 cm. PCR-based analyses,
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luciferase reporter assays, cell viability, and statistical methods are detailed in
the Supplemental Experimental Procedures.
Immunodetection Analyses
For western blots, samples were lysed 1:1 in either 23 urea disruption buffer
(6 M urea, 2 M b-mercaptoethanol, and 4% SDS) or 23 Laemmli’s sample
buffer, nucleic acids sheared by passing three times through a 29G needle,
and boiled for 10 min prior to protein separation by SDS-PAGE on NuPAGE
Novex 4%–12% Bis-Tris gradient gels (Life Technologies). Proteins were de-
tected by western blotting following transfer to polyvinylidene fluoride
(PVDF) membranes. Antibodies used, as well as immunofluorescence assays,
are described in the Supplemental Experimental Procedures.
SILAC Cell Culture, Treatments, and TAP Purification
Proteomic experiments were performed using the SILAC technique that allows
for quantitative data analysis. In brief, cells were grown in DMEM with L-lysine
and L-arginine replaced with stable isotope forms (Cambridge Isotope Labo-
ratories) in various combinations depending on treatment (see the Supple-
mental Experimental Procedures). SILAC DMEM was supplemented with
10% dialyzed FCS. The modified denaturing TAP procedure has been
described previously (Golebiowski et al., 2010). In brief, after treatment, cells
were washed with PBS and lysed with denaturing buffer containing 2%
SDS. For large-scale mass spectrometry experiments with three conditions,
all resulting lysates were mixed 1:1:1 (based on total protein), and a crude
sample (1% of the total) was analyzed separately from the remaining
99% material, which was subjected to TAP purification (see the Supple-
mental Experimental Procedures). Both samples were resolved on NuPAGE
Novex 10% Bis-Tris polyacrylamide gels prior to gel slice excision, in-gel
tryptic digestion, and liquid chromatography-tandem mass spectrometry
(LC-MS/MS). Detailed methods as well as information on data processing
are included in the Supplemental Experimental Procedures. Small-scale puri-
fications were done in essentially the same way, although lysates were
handled separately and analyzed by SDS-PAGE and western blot.
shRNA Lentivirus Library Preparation and Functional Screening
A customized 129 component sequence-verified MISSION shRNA lentiviral
plasmid (pLKO.1-puro) library targeting 44 genes of interest (as well as a nega-
tive control scramble sequence) (Table S6) was purchased from Sigma-Al-
drich. Lentiviral stocks were prepared by co-transfecting each pLKO.1-puro
plasmid with pMD2.G and pCMVdR8.91 into 293T cells using PEI. Lentiviral
supernatants were harvested 60 hr post-transfection, aliquoted, and stored
at 80C. For screening gene depletion impact on IAV, A549 cells in 24-well
plates were transduced with the appropriate lentivirus stock for 48 hr in the
presence of 8 mg/ml polybrene (Millipore). Very high transduction efficiency
for a subset of our lentiviral preparationswas confirmed using puromycin treat-
ment of parallel plates. Transduced cells were infected with WSN at an MOI of
0.001 plaque-forming units (PFU)/cell, and supernatants were collected and
titrated by plaque assay at 24 and 48 hr.
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